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Background: A number of observational studies were carried out in patients with isolated 
Raynaud's phenomenon (RP) to investigate the predictors of transition to RP secondary to 
connective tissue diseases (CTDs). Data from a meta-analysis, including studies until June 
1996, highlighted the potential role of nailfold capillaroscopy and/or antinuclear antibodies 
(ANAs) in predicting such transition [1]. 
Objectives: To provide an updated comprehensive review and meta-analysis on the rates and 
the role of predictors of transition to CTDs and systemic sclerosis (SSc) in patients with RP. 
Methods: A systematic search of observational studies was undertaken using Medline and 
Embase (07/1996 to 08/2014). From the list of records retrieved, studies were screened by 
titles/abstracts and the full papers were sought where abstracts were felt to be relevant. Cohort 
studies reporting incidence and risk factors of transition from primary RP (pRP) or suspected 
secondary RP (ssRP) to CTDs were selected and data collected in ad hoc forms. pRP was defined 
according to Leroy and Medsger criteria (no history or physical findings suggestive of a 
secondary cause, normal capillaroscopy, negative serologic findings); ssRP was defined in 
presence of positive ANAs and/or abnormal capillaroscopy (even in association with symptoms 
or physical findings suggestive of a secondary cause without fulfilling criteria for a definite CTD). 
Relative risk (RR) and 95% confidence interval (CI) were extracted or calculated to present the 
association between risk factors and transition to CTDs. Random effects model was used to pool 
the results. 
Results: From 2.221 articles captured, 36 met the predefined criteria, 29 were excluded on full 
text, and 7 selected studies provided information on transition from pRP and/or ssRP to 
secondary RP: 5 prospective and 2 retrospective cohort studies. Six studies included a total of 
4051 patients with pRP with a cumulative mean follow-up of 20241 person-years (mean follow-
up 4.9±2 years); a total of 1220 transitions to overt CTDs were recorded (pooled incidence rate 
2.5/100 person-years of observation, range 0–7.7); among these, 321 transitions were to SSc 
(pooled incidence rate 1.58/100 person-years, range 0–2.8). Five studies included 657 patients 
with ssRP with a cumulative mean follow-up of 2377 person-years (mean follow-up 3.6±1.1 
years); a total of 188 transitions to CTDs were recorded (pooled incidence rate 7.9/100 person-
years, range 3.3–26) and 135 to SSc (pooled incidence rate 5.7/100 person-years, range 2.1–
13). With respect to the patients with pRP, having ANA without capillary abnormalities provided 
a modest risk to develop SSc (pooled RR 2.8, CI 2.1–3.8), even weaker resulted the association 
between capillary abnormalities without ANA and the risk of SSc transition (RR 1.3, CI 0.7–2.4). 
On the other hand, the coexistence of ANA and abnormal capillaroscopy significantly increased 
the risk of transition to SSc (RR 8.1, CI 6.9–9.7). 
Conclusions: A low incidence rate of transition from pRP to overt CTDs was confirmed. In 
patients with ssRP, whilst accepting the influence of selection bias of different studies, there 
appears to be a strong risk of transition toward a CTD regarding the concomitant presence of 
ANAs and abnormal capillaroscopy. 
References: 
 
Spencer-Green G. Arch Intern Med. 1998;158(6):595–600. 
 
Disclosure of Interest: None declared 
DOI: 10.1136/annrheumdis-2016-eular.5250 
 
Citation: Ann Rheum Dis2016;75(Suppl2): 886 
 
